Compare iShares MSCI Canada (TSX) (EWC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Viatris Inc — how do they compare? iShares MSCI Canada (TSX) trades at $59.31, while Viatris Inc trades at $17.27 (market cap $19.44B). The key difference: Viatris Inc pays a 2.88% dividend while iShares MSCI Canada (TSX) pays none. Which is the better fit depends on your goals.
| EWC | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $59.49 | $17.39 |
52-Week Low | $45.86 | $8.74 |
Market Cap | — | $19.44B |
Enterprise Value | — | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.38, up 0.34% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong momentum near key resistance at $60, supported by positive Canadian economic news including trade surpluses and nuclear energy expansion plans. A dividend of $0.28 is scheduled for June 2026, adding income appeal.
Outlook remains positive due to Canada's economic recovery and commodity strength, though risks include US trade policy uncertainty and high RSI levels suggesting near-term consolidation. Institutional sentiment is bullish, with technical support at $59 providing a floor for potential gains.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
